[Caution] not approved anywhere. keep posts descriptive.
co-agonism. That is the whole post, but I will justify it. Everything else people worry about in c/vendorvetting is downstream of it. Titration speed, muscle cramps, the endless dose arguments — most of it resolves if you sort co-agonism out first, and almost nobody does. I say this having got it wrong for 15 months.…
Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.
amylin is not a GLP-1, posts conflating them get corrected
research use only, no human protocols in posts
The research community is small on cagrilintide. Forum lore changes faster than data.
Not convinced. The evidence does not support that reading.
CagriSema is a fixed combo in trials, not user-mixed
the mechanism is different, the side effect profile reflects it
Tracking number removed. It identifies both ends of a shipment.